Matinas Biopharma Stock Price - MTNB

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Matinas Biopharma Holdings Inc MTNB AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0092 0.58% 1.5892 1.61 1.52 1.61 1.58 11:44:26
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,045 615,948 $ 1.58 $ 971,037 2,397,907 0.501 - 2.18
Last Trade Time Type Quantity Stock Price Currency
11:44:26 3,100 $ 1.5892 USD

Matinas Biopharma Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 258.63M 162.74M $ -14.08M -0.15 - 152.11M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
5.04M $ - 0.00% 26.00 6.50%

more financials information »

Matinas Biopharma News

Loading Messages....

Latest MTNB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MTNB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.602.181.491.785,200,516-0.0108-0.68%
1 Month1.102.180.98021.443,966,2810.489244.47%
3 Months0.602.180.58181.301,682,5420.9892164.87%
6 Months0.812.180.58181.141,091,0230.779296.2%
1 Year0.802.180.5011.101,056,3990.789298.65%
3 Years3.994.350.32371.12832,895-2.40-60.17%
5 Years3.994.350.32371.12832,895-2.40-60.17%

Matinas Biopharma Description

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. Its lead anti-fungal product candidate, MAT2203, safely and effectively delivers anti-infective therapies utilizing its proprietary LNC formulation technology. In addition, it is pursuing the development of MAT9001 which is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins, and PCSK9 levels.


Your Recent History
AMEX
MTNB
Matinas Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.